Wall Street PR

Immunovative Launches New Site and Sees Huge Gain (IMUN)

Immunovative (OTC: IMUN) staged a huge rally today following the launch of the company’s new website and newsletter ImmuNews. The stock opened today’s trading session at a share price of $0.18, and rose quickly before 11:00 a.m. Immunovative steadily rallied for the rest of the day, and eventually closed today’s trading session at a share price of $0.28, or 60.6% higher than its previous close. Volume of the stock also surged to a total of 4.62 million shares, bypassing its average of 98,751 shares.

Today, July 30, 2012, Immunovative announced that it has launched a new websitewww.IMUN.com, that includes information on the company’s technology, product candidates, management team, videos and links to its social media sites.

In addition, Immunovative announced the launch of ImmuNews, a monthly newsletter designed to educate and inform its shareholders and other interested parties of news related to the field of cancer immunotherapy, and to provide updates on product development.

Several newsletters have promoted Immunovative. There are four results found on stockpromoters.com regarding the promotion of Immunovative. On Twitter, @pennystock24 noted that Penny Stock Wizards promoted Immunovative today.

Recent notable headlines for Immunovative also include:

  • July 27, 2012: Immunovative announced the formation of a Business Advisory Board and the appointment of Bruno Vanderschelden as Chairman. The Business Advisory Board is being formed to provide management with expertise and advice on strategies for raising capital, improving capital structure, and initiate the process to graduate to a senior stock exchange.
  • July 25, 2012: Immunovative announced the appointment of Professor Emmanuel Katsanis, MD, as Chief Medical Officer, Medical Monitor and Chairman of the Scientific Advisory Board.

Immunovative was formerly known as Novo Energies. The company is engaged in cancer treatment.

On December 12, 2011, Novo entered into a license agreement with Immunovative Therapies, pursuant to which Novo received a worldwide license to commercialize all the licensed products based on Immunovative’s current and future patents from the University of Arizona.

Immunovative is developing a class of immunotherapy drugs designed to harness the power of the immune system to treat cancer. The license granted covers two experimental products for the treatment of cancer in clinical development called AlloStim and Allo Vax, both of which are licensed products.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.